



1P-792-T025

Monoclonal Antibody to CD87 Phycoerythrin (PE) conjugated (25 tests)

Clone:	VIM5
Isotype:	Mouse IgG1
Specificity:	The mouse monoclonal antibody VIM5 recognizes CD87 (urokinase plasminogen activator receptor), a 36-68 kDa single-chain GPI-anchored glycoprotein expressed on granulocytes, monocytes/macrophages, dendritic cells, endothelial cells, fibroblasts and keratinocytes. HLDA VI; WS Code MR13
Regulatory Status:	RUO
Immunogen:	human myeloid cell line THP-1
Species Reactivity:	Human
Preparation:	The purified antibody is conjugated with R-Phycoerythrin (PE) under optimum conditions. The conjugate is purified by size-exclusion chromatography and adjusted for direct use. No reconstitution is necessary.
Storage Buffer:	The reagent is provided in stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide.
Storage / Stability:	Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Usage:	The reagent is designed for Flow Cytometry analysis of human blood cells using 10 µl reagent / 100 µl of whole blood or 10 ⁶ cells in a suspension. The content of a vial (0.25 ml) is sufficient for 25 tests.
Expiration:	See vial label
Lot Number:	See vial label
Background:	CD87, the urokinase plasminogen activator receptor (UPAR), is a GPI-anchored single chain glycoprotein of a 50-68 kDa, which is expressed on granulocytes, monocytes/macrophages, dendritic cells, endothelial cells, fibroblasts and keratinocytes. The urokinase plasminogen activator bound to CD87 converts plasminogen to plasmin, and being concentrated on the leading edge of migrating cells, it plays important role in cell adhesion and chemotaxis. CD87 binds to α1, α2, and α3 integrins, and can contribute to cancer cell invasion and metastasis. This antigen can also be used to study normal and abnormal granulopoiesis.
References:	*Elghetany MT, Patel J, Martinez J, Schwab H: CD87 as a marker for terminal granulocytic maturation: assessment of its expression during granulopoiesis. <i>Cytometry B Clin Cytom.</i> 2003 Jan;51(1):9-13. *Lanza F, Castoldi GL, Castagnari B, Todd RF 3rd, Moretti S, Spisani S, Latorraca A, Focarile E, Roberti MG, Traniello S: Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. <i>Br J Haematol.</i> 1998 Oct;103(1):110-23. *Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, Lee FY, Aichberger KJ, Manley PW, Fabbro D, Pickl WF, Sillaber C, Valent P: Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. <i>Haematologica.</i> 2007 Nov;92(11):1451-9.

For laboratory research only, not for drug, diagnostic or other use.



Antibodies

Unless indicated otherwise, all products are For Research Use Only and not for diagnostic or therapeutic use. Not for resale or transfer either as a stand-alone product or as a component of another product without written consent of EXBIO. EXBIO will not be held responsible for patent infringement or other violations that may occur with the use of our products. All orders are accepted subject to EXBIO's term and conditions which are available at www.exbio.cz.

For laboratory research only, not for drug, diagnostic or other use.

EXBIO Praha | Nad Safinou II 341 | 252 50 Vestec u Prahy | Czech Republic
Tel: +420 261 090 666 | Fax: +420 261 090 660 | orders@exbio.cz | www.exbio.cz